Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.2500
-0.02-7.78%
At close: -
$0.2515
0.001500.60%
After Hours: 7:59 PM EDT
Comments
Loading...
X4 Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:XFOR | Benzinga
X4 Pharmaceuticals Inc has a consensus price target of $3.69 based on the ratings of 8 analysts. The high is $10 issued by Canaccord Genuity on April 5, 2022. The low is $1 issued by B. Riley Securities on December 12, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co. on March 27, 2025, March 26, 2025, and February 7, 2025, respectively. With an average price target of $2 between HC Wainwright & Co., Cantor Fitzgerald, and HC Wainwright & Co., there's an implied 695.23% upside for X4 Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Cantor Fitzgerald
Stifel
B. Riley Securities
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for X4 Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/27/2025 | Buy Now | 496.42% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $1.5 → $1.5 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2025 | Buy Now | 1092.84% | Cantor Fitzgerald | Kristen Kluska69% | $3 → $3 | Reiterates | Overweight → Overweight | Get Alert |
| 02/07/2025 | Buy Now | 496.42% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $1.5 → $1.5 | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 496.42% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $1.5 → $1.5 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 496.42% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $5 → $1.5 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 1490.46% | Stifel | Stephen Willey51% | $5 → $4 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 1888.07% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 1888.07% | Cantor Fitzgerald | Kristen Kluska69% | $5 → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 04/30/2024 | Buy Now | 1888.07% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $3 → $5 | Maintains | Buy | Get Alert |
| 03/22/2024 | Buy Now | 1092.84% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $3 → $3 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2023 | Buy Now | 297.61% | B. Riley Securities | Kalpit Patel38% | $3 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 08/11/2023 | Buy Now | 1092.84% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $3 | Reiterates | Buy → Buy | Get Alert |
| 05/17/2023 | Buy Now | 1888.07% | Stifel | Stephen Willey51% | $4 → $5 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 1092.84% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $3 | Reiterates | → Buy | Get Alert |
| 04/10/2023 | Buy Now | 1092.84% | B. Riley Securities | Mayank Mamtani71% | $7 → $3 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | 1490.46% | Oppenheimer | Leland Gershell69% | $5 → $4 | Maintains | Outperform | Get Alert |
| 03/22/2023 | Buy Now | 1092.84% | Cantor Fitzgerald | Kristen Kluska69% | → $3 | Maintains | Overweight | Get Alert |
| 03/22/2023 | Buy Now | 1092.84% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $5 → $3 | Maintains | Buy | Get Alert |
| 12/22/2022 | Buy Now | 1092.84% | Cantor Fitzgerald | Kristen Kluska69% | → $3 | Initiates | → Overweight | Get Alert |
| 12/12/2022 | Buy Now | 1092.84% | Piper Sandler | Edward Tenthoff51% | → $3 | Initiates | → Overweight | Get Alert |
| 11/30/2022 | Buy Now | 1888.07% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $3.5 → $5 | Maintains | Buy | Get Alert |
| 05/19/2022 | Buy Now | 2683.3% | B. Riley Securities | Mayank Mamtani71% | $10 → $7 | Maintains | Buy | Get Alert |
| 05/13/2022 | Buy Now | 3279.72% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $11 → $8.5 | Maintains | Buy | Get Alert |
| 04/05/2022 | Buy Now | 3876.14% | Canaccord Genuity | Arlinda Lee58% | $20 → $10 | Maintains | Buy | Get Alert |
FAQ
What is the target price for X4 Pharmaceuticals (XFOR) stock?
The latest price target for X4 Pharmaceuticals (NASDAQ:XFOR) was reported by HC Wainwright & Co. on March 27, 2025. The analyst firm set a price target for $1.50 expecting XFOR to rise to within 12 months (a possible 496.42% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for X4 Pharmaceuticals (XFOR)?
The latest analyst rating for X4 Pharmaceuticals (NASDAQ:XFOR) was provided by HC Wainwright & Co., and X4 Pharmaceuticals reiterated their buy rating.
When was the last upgrade for X4 Pharmaceuticals (XFOR)?
There is no last upgrade for X4 Pharmaceuticals
When was the last downgrade for X4 Pharmaceuticals (XFOR)?
The last downgrade for X4 Pharmaceuticals Inc happened on December 12, 2023 when B. Riley Securities changed their price target from $3 to $1 for X4 Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for X4 Pharmaceuticals (XFOR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of X4 Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for X4 Pharmaceuticals was filed on March 27, 2025 so you should expect the next rating to be made available sometime around March 27, 2026.
Is the Analyst Rating X4 Pharmaceuticals (XFOR) correct?
While ratings are subjective and will change, the latest X4 Pharmaceuticals (XFOR) rating was a reiterated with a price target of $1.50 to $1.50. The current price X4 Pharmaceuticals (XFOR) is trading at is $0.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.